XML 23 R5.htm IDEA: XBRL DOCUMENT v3.25.4
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($)
$ in Thousands
Common Stock
Additional Paid-In Capital
Retained Earnings
Accumulated Other Comprehensive Earnings (Loss)
Noncontrolling Interest (NCI)
Total
Beginning balance at Dec. 31, 2022 $ 61,618 $ 294,029 $ 2,217,410 $ (9,075) $ 32,841 $ 2,596,823
Increase (Decrease) in Stockholders' Equity            
Net earnings (loss)     514,312   663 514,975
Foreign currency translation adjustment       9,762 4,267 14,029
Unrealized gain on investments and other       419   419
Other   (817)     930 113
Distributions to NCI         (7,355) (7,355)
Purchase of remaining NCI of subsidiary   (1,210)     (917) (2,127)
Cash dividends     (68,238)     (68,238)
Issuance of shares under employee stock purchase plan 33 2,717       2,750
Issuance of shares under stock grant programs 821 14,485 22     15,328
Issuance of shares under deferred compensation plans 124 (124)        
Repurchase of shares (975)   (81,174)     (82,149)
Expense associated with share-based compensation arrangements   34,727       34,727
Accrued expense under deferred compensation plans   10,895       10,895
Ending balance at Dec. 30, 2023 61,621 354,702 2,582,332 1,106 30,429 3,030,190
Increase (Decrease) in Stockholders' Equity            
Net earnings (loss)     414,560   5,413 419,973
Foreign currency translation adjustment       (16,428) (3,441) (19,869)
Unrealized gain on investments and other       11   11
Other   (242)       (242)
Distributions to NCI         (11,848) (11,848)
Purchase of remaining NCI of subsidiary   8,400       8,400
Cash dividends     (80,782)     (80,782)
Issuance of shares under employee stock purchase plan 28 2,784       2,812
Issuance of shares under stock grant programs 380 5,923 77     6,380
Issuance of shares under deferred compensation plans 104 (104)        
Repurchase of shares (1,409) (17,686) (140,907)     (160,002)
Expense associated with share-based compensation arrangements   37,938       37,938
Accrued expense under deferred compensation plans   11,664       11,664
Ending balance at Dec. 28, 2024 60,724 403,379 2,775,280 (15,311) 20,553 3,244,625
Increase (Decrease) in Stockholders' Equity            
Net earnings (loss)     294,792   1,617 296,409
Foreign currency translation adjustment       15,653 2,720 18,373
Unrealized gain on investments and other       1,222   1,222
Other   (3,663)       (3,663)
Distributions to NCI         (3,005) (3,005)
Cash dividends     (82,350)     (82,350)
Issuance of shares under employee stock purchase plan 30 2,441       2,471
Issuance of shares under stock grant programs 223 3,156 270     3,649
Issuance of shares under deferred compensation plans 114 (114)        
Repurchase of shares (4,499) (9,503) (428,617)     (442,619)
Expense associated with share-based compensation arrangements   37,583       37,583
Accrued expense under deferred compensation plans   11,549       11,549
Ending balance at Dec. 27, 2025 $ 56,592 $ 444,828 $ 2,559,375 $ 1,564 $ 21,885 $ 3,084,244